Successful renegotiation of API supply agreement
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Botanix Pharmaceuticals Limited has successfully renegotiated its active pharmaceutical ingredient supply agreement, rescheduling purchases to later years. The company aims to establish an additional API supplier to reduce supply chain risks and potentially lower costs significantly. This amendment is expected to enhance Botanix's financial position and support its plans for the Sofdra product.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings CallBotanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- S&P DJI Announces March 2026 Quarterly Rebalance
- Appendix 4D and Half Year Report
- Botanix Receives Capital Raise Commitments of A$45 Million
- Trading Halt
- Pause in Trading
Later from Botanix Pharmaceuticals
- Botanix reaches term sheet agreement with 2nd API supplier
- Botanix Quarterly Activities Report and Appendix 4C Q3 FY26
- Intention to Grant a European patent on Sofdra applicator
- Notice of Allowance for US patent on Sofdra drug substance
- Botanix Quarterly Activities Report and Appendix 4C Q4 FY26
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals